Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total transaction of $859,716.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $31,045.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Price Performance

United Therapeutics stock opened at $233.85 on Friday. The stock has a 50-day moving average price of $233.74 and a two-hundred day moving average price of $228.81. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a market capitalization of $11.00 billion, a PE ratio of 11.79 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. United Therapeutics’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 earnings per share. Analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $213.00 to $215.00 in a report on Monday, February 12th. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. HC Wainwright restated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, Wedbush reiterated an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $294.25.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in United Therapeutics in the fourth quarter valued at approximately $100,519,000. Avidity Partners Management LP acquired a new position in shares of United Therapeutics in the 4th quarter worth approximately $52,158,000. Comerica Bank boosted its stake in shares of United Therapeutics by 2,697.2% in the 3rd quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after purchasing an additional 150,989 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of United Therapeutics by 309.7% during the fourth quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock worth $29,501,000 after buying an additional 101,419 shares during the period. Finally, TD Asset Management Inc raised its stake in United Therapeutics by 1,066.4% during the fourth quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock worth $18,240,000 after buying an additional 75,839 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.